AP756A - Dipeptide compounds which are growth hormone secretagoques. - Google Patents

Dipeptide compounds which are growth hormone secretagoques. Download PDF

Info

Publication number
AP756A
AP756A APAP/P/1996/000881A AP9600881A AP756A AP 756 A AP756 A AP 756A AP 9600881 A AP9600881 A AP 9600881A AP 756 A AP756 A AP 756A
Authority
AP
ARIPO
Prior art keywords
compounds
group
alkyl
growth hormone
phenyl
Prior art date
Application number
APAP/P/1996/000881A
Other versions
AP9600881A0 (en
Inventor
Philip A Carpino
Silva-Jardine Paul Andrew Da
Bruce Allen Lefker
John A Ragan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600881A0 publication Critical patent/AP9600881A0/en
Application granted granted Critical
Publication of AP756A publication Critical patent/AP756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cooling Or The Like Of Electrical Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

This invention is directed to compounds of the formula and the pharmaceulically-acceptable salts thereof, where the subslituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this Invention are useful for (the treatment and prevention of osleoporosis. congestive heart failure, frailly associated with aging, obesity; accelerating bone fracture repair, attenuating .protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeoslasis or renal homeostasis. The compounds of (he present invention are also useful in treating osleoporosis when used in combination with: a bisphosphonale compound such as alendronale; estrogen. premarin, and optionally progesterone; an estrogen agonist or antagonist; or cslcilonin, and pharmaceutical compositions useful therefor. Further, (he presenl invention is directed (o pharmaceutical compositions useful for increasing (he endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growlh hormone secretagogue selected from GHRP-6. Hexarelin. GHRP-1. growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed lo intermediates useful in the preparation of compounds of formula I.

Description

HETEROCYCLIC COMPOUNDS
This invention relates to dipeptide compounds which are growth hormone secretagogues and are useful for the treatment and prevention of osteoporosis.
Background of the Invention
Growth hormone (GH), which is secreted from the pituitary gland, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic process of the body: 1. Increased rate of protein synthesis in substantially all cells of the body; 2. Decreased rate of carbohydrate utilization in cells of the body; 3. increased mobilization of free fatty acids and use of fatty acids for energy.
Deficiency in growth hormone results in a variety of medical disorders. In children, it causes dwarfism. In adults, the consequences of acquired GH deficiency include profound reduction in lean body mass and concomitant increase in total body fat, particularly in the truncal region. Decreased skeletal and cardiac muscle mass and muscle strength lead to a significant reduction in exercise capacity. Bone density is also reduced. Administration of exogenous growth hormone has been shown to reverse many of the metabolic changes. Additional benefits of therapy have included reduction in LDL cholesterol and improved psychological well-being.
In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering an agent which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection. Initially the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in an expensive product, and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone (e.g., Jacob-Creutzfeld disease). Recently, recombinant growth hormone has become available which, while no Jonger carrying any risk of disease transmission, is still a very expensive product .which must be given by injection or by a nasal spray.
Most GH deficiencies are caused by defects in GH release, not primary defects in pituitary synthesis of GH. Therefore, an alternative strategy for normalizing serum GH levels is by stimulating its release from somatotrophs. Increasing GH secretion can be achieved by stimulating or inhibiting various neurotransmitter systems in the brain and hypothalamus. As a result, the development of synthetic growth hormone-releasing agents to stimulate pituitary GH secretion are being pursued, and may have several advantages over expensive and inconvenient GH replacement therapy. By acting along physiologic regulatory pathways, the most desirable agents would stimulate pulsatile GH secretion, and excessive levels of GH that have been associated with the undesirable side effects of exogenous GH administration would be avoided by virtue of intact negative feedback loops.
Physiologic and pharmacologic stimulators of GH secretion include arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GHRF) or an c unknown endogenous growth hormone-releasing hormone or all of these.
Other compounds have been developed which stimulate the release of endogenous growth hormone such as analogous peptidyl compounds related to GRF or the peptides of U.S. Patent 4,411,890. These peptides, while considerably smaller than growth hormones are still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. WO 94/13696 refers to certain spiropiperidines and homologues which promote release of growth hormone. Preferred compounds are of the general structure shown below.
\N0 94/11012 refers to certain dipeptides that promote release of growth hormone. These dipeptides have the general structure
where L is
The compounds of WO 94/11012 and WO 94/13696 are reported to be useful in the treatment of osteoporosis in combination with parathyroid hormone or a bisphosphonate.
Summary of the Invention
This invention provides compounds of the formula:
the racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically-acceptable salts and prodrugs thereof, wherein e is 0 or 1; n and w are each independently 0, 1 or 2, provided that w and n cannot both be 0 at
I the same time; Y is oxygen or sulfur; R1 is hydrogen, -CN, -(CH2)qN(X6)C(O)X6, -(CH2)qN(X6)C(0)(CH2)t-A1, -(CH2)qN(X6)S02(CH2)t-A1,-(CH2)qN(X6)SO2X6,-(CH2)qN(X6)C(0)N(X6)(CH2),-A1, -(CH2)qN(X6)C(O)N(X6)(X6),-(CH2)qC(O)N(X6)(X6), -(CH2)qC(O)N(X6)(CH2)rA1, -(CH2)qC(0)0X6, -(CH2)qC(O)O(CH2)t-A1, -(CH2)qOX6, -(CH2)qOC(O)X6, -(CH2)qOC(O)(CH2)t-A1, -(CH2)qOC(O)N(X6)(CH2)t-A1, -(CH2)qOC(O)N(X6)(X6), -(CH2)qC(O)X6, -(CH2)qC(O)(CH2)t-A1, -(CH2)qN(X6)C(O)OX®, -(CH2)qN(X6)SO2N(X6)(X6), -(CH^O)^6 -(CH2)qS(O)m(CH2)t-A1, -(CrC10)alkyl, -(CH2)rA1, -(CH2)q-(C3-C7)cycloalkyl, -(CH2)q-Y1-(CrC6)alkyl, -(CH2)q-Y1-(CH2)t-A1 or -(CH2)q-Y1-(CH2)t-(C3-C7)cycloalkyl; where the alkyl and cycloalkyl groups in the definition of R1 are optionally substituted with (CrC4)alkyl, hydroxyl, (Ci-C4)alkoxy, carboxyl, -CONH2, -S(O)m(Ci-C6)alkyl, -CO2(C1-C4)alkyl ester, 1 H-tetrazol-5-yl or 1, 2 or 3 fluoro; Y1 is O, S(O)m, -C(O)NX6-, -CH=CH-, -CO, -N(Xe)C(O)-, -C(O)NX6-, -0(0)0-, -OC(0)N(X6)- or -0C(0)-;
q is Ο, 1, 2, 3 or 4; t is 0, 1, 2 or 3; said (CH2)q group and (CH2)t group may each be optionally substituted with hydroxyl, (C1-C4)alkoxy, carboxyl, -CONH2, -S(O)m(Ci-C6)alkyl, -CO2(Ci-C4)alkyl ester, 1 H-tetrazol-5-yl, 1, 2 or 3 fluoro, or 1 or 2 (Cr C4)aikyl; R2 is hydrogen, (Ci-C8)alkyl, -(C0-C3)alkyl-(C3-C8)cycloalkyl, -{CT-CJalkyl-A1 or A1; where the alkyl groups and the cycloalkyl groups, in the definition of R2 are optionally substituted with hydroxyl, -C(O)OX6, -C(O)N(X5)(Xe), -ΝίΧθχΧ6), -S(O)m(CrC6)alkyl, -C(O)A1, -C(O)(X6), CF3, CN or 1, 2 or 3 halogen; R3 is A1, (CrCwJalkyl, -(CrC6)alkyl-A1, -(CrC6)alkyl-(C3-C7)cycloalkyl, -(C1-C5)alkyl-X1-(C1-C5)alkyl, -(CrC5)alkyl-X1-(Co-C5)alkyl-A1 or -(Ci-CsJalkyl-X^C-i-CsJalkyl-CCTj-CyJcycloalkyl; where the alkyl groups in the definition of R3 are optionally substituted with, -S(O)m(CrC6)alkyl, -C(O)OX3,1, 2, 3, 4 or 5 halogens, or 1, 2 or 3 OX3; X1 is O, S(O)m, -N(X2)C(O)-, -C(O)N(X2)-, -OC(O)-, -C(O)O-, -cx2=cx2-, -N(X2)C(O)O-, -OC(O)N(X2)- or -C=C-; R4 is hydrogen, (Ci-O6)alkyl or (C3-C7)cycloalkyl, or R4 is taken together with R3 and the carbon atom to which they are attached and form (C5-C7)cycloalkyl, (C5-C7)cycloalkenyl, a partially saturated or fully saturated 4- to 8-membered ring having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, or is a bicyclic ring system consisting of a partially saturated or fully saturated 5- or 6-membered ring, fused to a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen; X4 is hydrogen or (C-,-C6)alkyl or X4 is taken together with R4 and the nitrogen atom to which X4 is attached and the carbon atom to which R4 is attached and form a five to seven membered ring; R6 is a bond or is
where a and b are independently 0,1, 2 or 3;
X5 and X5a are each independently selected from the group consisting of hydrogen, trifluoromethyl, A1 and optionally substituted (C-|-C6)alkyl; the optionally substituted (C-|-C6)a,ky· in the definition of X5 and X5a is optionally substituted with a substituent selected from the group consisting of A1, OX2, -S(O)m(CrC6)alkyl, -C(O)OX2, (C3-C7)cycloalkyl, -N(X2)(X2) and -C(G)N(X2)(X2); or the carbon bearing X5 or X5a forms one or two alkylene bridges with the nitrogen atom bearing R7 and R8 wherein each alkylene bridge contains 1 to 5 carbon atoms, provided that when one alkylene bridge is formed then X5 or X5a but not both may be on the carbon atom and R7 or R8 but not both may be on the nitrogen atom and further provided that when two alkylene bridges are formed then X5 and X5a cannot be on the carbon atom and R7 and R8 cannot be on the nitrogen atom; or Xs is taken together with X5a and the carbon atom to which they are attached and form a partially saturated or fully saturated 3- to 7-membered ring, or a partially saturated or fully saturated 4- to 8-membered ring having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen; or X5 is taken together with X5a and the carbon atom to which they are attached and form a bicyclic ring system consisting of a partially saturated or fully saturated 5- or 6-membered ring, optionally having 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated or fully unsaturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen; Z1 is a bond, O or N-X2, provided that when a and b are both 0 then Z1 is not N-X2 or O; R7 and R8 are independently hydrogen or optionally substituted (CrCgJalkyl; where the optionally substituted (CrC6)alkyl in the definition of R7 and R8 is optionally independently substituted with A1, -CiOJO-iCvCeJalkyl, -S(O)m(Ci-C6)alkyl, 1 to 5 halogens, 1 to 3 hydroxy, 1 to 3 -O-C(O)(Cr C10)alkyl or 1 to 3 (Ci-C6)alkoxy; or R7 and R8 can be taken together to form -(CH2)r-L-(CH2)r-; where L is C(X2)(X2), S(O)m or N(X2); A1 for each occurrence is independently (C5-C7)cycloalkenyl, phenyl or a partially saturated, fully saturated or fully unsaturated 4- to 8-membered ring optionally having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, a bicyclic ring system consisting of a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated or fully unsaturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen; A1 for each occurrence is independently optionally substituted, in one or optionally both rings if A1 is a bicyclic ring system, with up to three substituents, each substituent independently selected from the group consisting of F, Cl, Br, I, OCF3, OCF2H, CF3, CH3, OCH3, -OX6, -C(O)N(X6)(X6), -C(O)OX6, oxo, (C-|-C6)alkyl, nitro, cyano, benzyl, -S(O)m(Ci-C6)alkyl, 1H-tetrazol-5-yl, phenyl, phenoxy, phenylalkyloxy, halophenyl, methylenedioxy, -N(X6)(X6), -N(X6)C(O)(X6), -SO2N(Xs)(X6), -N(X6)SO2-phenyl, -N(X6)SO2X6, -C0NX11X12, -SO2NX11X12, -NX6SO2X12, -NX6CONX11X12, -NX6SO2NX11X12, -NX6C(O)X12, imidazolyl, thiazolyl or tetrazoiyl, provided that if A1 is optionally substituted with methylenedioxy then it can only be substituted with one methylenedioxy; where X11 is hydrogen or optionally substituted (C1-C6)alkyl; the optionally substituted (CrC6)alkyl defined for X11 is optionally independently substituted with phenyl, phenoxy, (Cr C6)alkoxycarbonyl, -SfO^fCrCJalkyl 1 to 5 halogens, 1 to 3 hydroxy, 1 to 3 (C1-C10)alkanoyloxy or 1 to 3 (CrC6)alkoxy; X12 is hydrogen, (CrC6)alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl, provided that when X12 is not hydrogen, X12 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, CH3, 0CH3, OCF3 and CF3; or X11 and X12 are taken together to form -(CH2)r-L1-(CH2)r-; L1 is C(X2)(X2), O, S(0)m or N(X2); r for each occurrence is independently 1, 2 or 3; X2 for each occurrence is independently hydrogen, optionally substituted (Cr C6)alkyl, or optionally substituted (C3-C7)cycloalkyl, where the optionally substituted (CvC^alkyl and optionally substituted (C3-C7)cycloalkyl in the definition of X2 are optionally independently substituted with -SCO^C^-C^alkyl, -C(O)OX3, 1 to 5 halogens or 1 to 3 OX3; X3 for each occurrence is independently hydrogen or (CrCgJalkyl; X6 is independently hydrogen, optionally substituted (C-,-C6)alkyl, (C2-C6)halogenated alkyl, optionally substituted (C3-C7)cycloalkyl, (C3-C7)-halogenatedcycloalkyl, where optionally substituted (C-,-C6)alkyl and optionally substituted (C3-C7)cycloalkyl in the definition of X6 is optionally independently substituted by 1 or 2 (C^C^alkyl, hydroxyl, (CrC4) alkoxy, carboxyl, CONH2, -S(O)m(Ci-C6)alkyl> carboxylate (Cp C4)alkyl ester, or 1 H-tetrazol-5-yl; or when there are two X6 groups on one atom and both X6 are independently (Cr C6)alkyl, the two (C-,-C6)alkyl groups may be optionally joined and, together with the atom to which the two X6 groups are attached, form a 4- to 9- membered ring optionally having oxygen, sulfur or NX7; X7 is hydrogen or (CrC^alkyl optionally substituted with hydroxyl; and m for each occurrence is independently 0, 1 or 2; with the proviso that: X6 and X12 cannot be hydrogen when it is attached to C(O) or SO2 in the form C(O)X6, C(O)X12, SO2X6 or SO2X12; and when R6 is a bond then L is N(X2) and each r in the definition -(CH2)r-L-(CH2)r- is independently 2 or 3. A preferred group of compounds, designated the “A Group”, contains those compounds having the formula I as shown hereinabove wherein X4 is hydrogen; R4 is hydrogen or methyl; R7 is hydrogen or (CrC3)alkyl; R8 is hydrogen or (Ci-C3)alkyl optionally substituted with one or two hydroxyl groups; R is
where Z is a bond and a is 0 or 1; X5 and X5a are each independently hydrogen, trifluoromethyl, phenyl, optionally substituted (CrC6)alkyl;
where the optionally substituted (CrC^alkyl is optionally substituted with OX2, imidazolyl, phenyl, indolyl, p-hydroxyphenyl, (C5-C7)cycloalkyl, -S(O)m(CrC6)alkyl, -N(X2)(X2) or-C(O)N(X2)(X2); or X5 and R7 are taken together to form a (Ci-C5)alkylene bridge, and the other substituents not defined for the “A Group” compounds are as defined for formula (I) hereinabove. A group of compounds, which is preferred among the “A Group” of compounds, designated the “B Group”, contains those compounds of the ‘A Group”, having the formula I as shown hereinabove, wherein b is 0; X5 and X53 are each independently hydrogen, (C-,-C3)alkyl or hydroxy(C-|-C3)alkyl; R3 is selected from the group consisting of 1-indolyl-CH2-, 2-indolyl-CH2-, 3-indolyl-CH2-, 1-naphthyl-CH2-, 2-naphthyl-CH2-, 1-benzimidazolyl-CH2-, 2-benzimidazolyl-CH2-, phenyHC-i-C^alkyl-, 2-pyridyl-(C1-C4)alkyl-, 3-pyridyl-(CrC4)alkyl-, 4-pyridyl-(Ci-C4)alkyl-, phenyl-CH2-S-CH2-, thienyl-(CrC4)alkyl-, phenyl-(C0-C3)aIkyl-O-CH2-, phenyl-CH2-O-phenyl-CH2-, and 3-benzothienyl-CH2-; where the aryl portion(s) of the groups defined for R3 are optionally l substituted with one to three 'substituents, each substituent being independently selected from the group consisting of methylenedioxy, F, Cl, CH3, OCH3i OCF3i OCF2H and CF3. A group of compounds, which is preferred among the “B Group” of compounds, designated the “C Group", contain those compounds of the “B Group”, having the formula I as shown hereinabove, wherein R4 is hydrogen; a is 0; n is 1 or 2; w is 0 or 1; X5 and X5a are each independently, hydrogen, methyl or hydroxymethyl, provided that when X5 is hydrogen then X5a is not hydrogen; R7 and R8 are each hydrogen; and R3 is phenyl-CH2-O-CH2-, phenyl-CH2-S-CH2-, 1-naphthyl-CH2-, 2-naphthyl-CH2-, phenyl-(CH2)3- or 3-indolyl-CH2-; where the aryl portion of the groups defined for R3 is optionally substituted with one to three substituents, each substituent being independently selected from the group consisting of fluoro, chloro, methyl, OCH3, OCF2H, OCF3 and ' cf3. A group of compounds, which is preferred among the “C Group’ of compounds, designated the “D Group", contains those compounds of the “C Group”, having the formula I as shown hereinabove, wherein R1 is -(CH2)t-A1, -{CH2)q-(C3-C7)cycloalkyl or (C-,-Ci0)alkyl; where A1 in the definition of R1 is optionally substituted with one to three substituents, each substituent being independently selected from the group consisting of fluoro, chloro, methyl, OCH3, OCF2H, OCF3 and CF3; the cycloalkyl and alkyl groups in the definition of R1 are optionally substituted with (C1-C4)alkyl, hydroxyl, (Ci-C4)alkoxy, carboxyl, CONH2, -S(0)m(CrC6)alkyl, -CO^Ct-C4)alkyl ester, 1 H-tetrazol-5-yl or 1 to 3 fluoro; Y is O; R2 is hydrogen, -(Co-C3)alkyl-(C3-C8)cycloalkyl, phenyl or (Ci-C8)alkyl where the (Ci-C8)alkyl group is optionally substituted with hydroxyl, -CF3 or 1 to 3 halogen. A group of compounds, which is preferred among the “D Group” of compounds, designated the Έ Group", contains those compounds of the “D Group” wherein w is 0 and n is 1.
Another group of compounds, which is preferred among the “D Group” of compounds, designated the “F Group", are those compounds of the “D Group”, having the formula I as shown hereinabove, wherein e is 0; n and w are each 1; R1 is -(CH2)t-A1; where A1 in the definition of R1 is phenyl, thienyl, thiazolyl, pyridyl or pyrimidyi which is optionally substituted with one to three substituents, each substituent being independently selected from the group consisting of F, Cl, Me, OMe, CF3, OCF3 and OCF2H; t is 0,1 or 2; and R3 is phenyl-CH2-O-CH2-, phenyl-(CH2)3- or 3-indolyl-CH2-, where the aryl portion is optionally substituted with one to three substituents, each substituent being independently selected from the group consisting of F, Cl, Me, OMe, CF3, OCF3 or OCF2H. A group of compounds, which is preferred among the “F Group" of compounds, designated the “G Group", contains those compounds of the “F Group”, having the formula I as shown hereinabove, wherein X5 and X5a are each methyl; R1 - is -CH2-phenyl, -CH2~4-fluoro-phenyl, -CH2-pyridyl or -CH2-thiazolyl and R2 is hydrogen, methyl, ethyl, t-butyl or -CH2CF3. A group of compounds, which is preferred among the “G Group” of compounds, designated the “G1 Group”, contains those compounds of the “G Group”, and have the formula
the racemic-diastereomeric mixtures and optical isomers of said compounds wherein R1 is -CH2-phenyl, R2 is methyl and R3 is -(CH2)3-phenyl; R1 is -CH2-phenyl, R2 is methyl and R3 is 3-indolyl-CH2-; R1 is -CH2-phenyl, R2 is ethyl and R3 is 3-indolyl-CH2-; R1 is -CH2-4-fluoro-phenyl, R2 is methyl and R3 is 3-indolyl-CH2-; R1 is -CH2-phenyl, R2 is methyl and R3 is -CH2-O-CH2-phenyl; R1 is -CH2-phenyl, R2 is ethyl and R3 is -CH2-O-CH2-phenyl; R1 is -CH2-phenyl, R2 is -CH2-CF3 and R3 is -CH2-O-CH2-phenyl; R1 is -CH2-4-fiuoro-phenyl, R2 is methyl and R3 is -CH2-O-CH2-phenyl; R1 is -CH2-phenyl, R2 is t-butyl and R3 is -CH2-O-CH2-phenyl; or R1 is -CH2-phenyl, R2 is methyl and R3 is -CH2-O-CH2-3,4-di-fluoro-phenyl.
The diastereomeric mixture of 2-amino-N-[2-(3a-(R,S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-(3,4-difluoro-benzyl-oxymethyl)-2-oxo-ethyl]-2-methyl-propionamide is preferred among the “G1 Group” of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture. A group of compounds, which is preferred among the “G Group" of compounds, designated the “H Group”, contains those compounds of the “G Group”, having the formula I as shown hereinabove, wherein R1 is -CH2-phenyl and R3 is phenyl-(CH2)3-.
The diastereomeric mixture of 2-amino-N-[1-(3a-(R,S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridine-5-carbonyI)-4-phenyl-(R)-butyl]-isobutyramide is preferred among the “H Group’ of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture.
A group of compounds, which is preferred among the “G Group” of compounds, designated the “I Group”, contains those compounds of the “G Group” wherein R1 is -CH2-phenyl or -CH2-4-fluoro-phenyl and R3 is 3-indolyl-CH2-.
The diastereomeric mixture of 2-amino-N-[2-(3a-(R,S)-benzyl-2-methyi-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-(1H-indol-3-ylmethyl)-2-oxo-ethyl]-isobutyramide is preferred among the “I Group” of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture.
The diastereomeric mixture of 2-amino-N-[2-(3a-(R,S)-benzyl-2-ethyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-(1H-indol-3-ylmethyl)-2-oxo-ethyl]-isobutyramide is also preferred among the “I Group" of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture.
The diastereomeric mixture of 2-amino-N-[2-[3a-(R,S)-(4-fluoro-benzyl)-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl]-1-(R)-(1H-indol-3-ylmethyl)-2-oxo-ethyl]-isobutyramide is also preferred among the “I Group” of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture. A group of compounds which is preferred among the “G Group” of compounds, designated the “J Group”, contains those compounds of the “G Group” wherein R1 is -CH2-phenyl or -CH2-4-fIuoro-phenyl and R3 is phenyl-CH2-O-CH2-.
The diastereomeric mixture of 2-amino-N-[2-(3a-(R,S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide is preferred among the “J Group” of compounds, the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture, the 3a-(R) isomer is preferred over the 3a-(S) isomer, and the L-tartaric acid salt of the 3a-(R) isomer is a preferred salt.
The diastereomeric mixture of 2-amino-N-[2-(3a-(R,S)-benzyl-2-ethyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide is also preferred among the “J Group” of compounds and the separated 3a-(R) and 3a-(S) isomers are preferred of the diastereomeric mixture.
The diastereomeric mixture of 2-amino-N-{2-[3a-(R,S)-benzyl-3-oxo-2-(2,2,2-triflijoro-ethyl)-213,3a14,6,7-hexahydro-pyrazolo[413-c]pyridin-5-yl]-'l-(R)- - benzyloxymethyl-2-oxo-ethyl}-isobutyramide is also preferred among the “J Group”

Claims (1)

  1. Original document published without claims.
APAP/P/1996/000881A 1995-12-28 1996-11-14 Dipeptide compounds which are growth hormone secretagoques. AP756A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US946995P 1995-12-28 1995-12-28

Publications (2)

Publication Number Publication Date
AP9600881A0 AP9600881A0 (en) 1997-01-31
AP756A true AP756A (en) 1999-08-06

Family

ID=21737850

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1996/000881A AP756A (en) 1995-12-28 1996-11-14 Dipeptide compounds which are growth hormone secretagoques.
APAP/P/1999/001555A AP860A (en) 1995-12-28 1999-05-27 Dipeptide compounds which are growth hormone secretegoques.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001555A AP860A (en) 1995-12-28 1999-05-27 Dipeptide compounds which are growth hormone secretegoques.

Country Status (43)

Country Link
US (7) US6124264A (en)
EP (1) EP0869968B1 (en)
JP (2) JP3511382B2 (en)
KR (1) KR100320167B1 (en)
CN (1) CN1113895C (en)
AP (2) AP756A (en)
AR (2) AR004367A1 (en)
AT (1) ATE361314T1 (en)
AU (1) AU716934B2 (en)
BG (1) BG64055B1 (en)
BR (1) BR9612465B1 (en)
CA (1) CA2241725C (en)
CO (1) CO4480108A1 (en)
CZ (1) CZ293423B6 (en)
DE (1) DE69637063T2 (en)
DK (1) DK0869968T3 (en)
EG (1) EG24195A (en)
ES (1) ES2285715T3 (en)
GT (1) GT199600100A (en)
HN (1) HN1996000085A (en)
HR (1) HRP960618B1 (en)
HU (1) HUP9901246A3 (en)
IL (4) IL138909A0 (en)
IS (1) IS4758A (en)
MA (1) MA26415A1 (en)
MX (1) MX9805157A (en)
MY (1) MY135727A (en)
NO (1) NO325135B1 (en)
NZ (1) NZ322172A (en)
OA (1) OA10702A (en)
PE (1) PE30398A1 (en)
PL (1) PL186916B1 (en)
PT (1) PT869968E (en)
RS (1) RS49926B (en)
SA (1) SA97170581B1 (en)
SI (1) SI0869968T1 (en)
SK (1) SK285678B6 (en)
TN (1) TNSN96172A1 (en)
TR (1) TR199801233T2 (en)
TW (1) TW432073B (en)
UA (1) UA66754C2 (en)
WO (1) WO1997024369A1 (en)
ZA (1) ZA9610858B (en)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
GB2338235B (en) 1997-04-15 2001-11-14 Csir Appetite suppressing plant extracts
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA64751C2 (en) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Treatment of insulin tolerance using substances increasing growth hormone secretion
UA53716C2 (en) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
WO1998058947A1 (en) 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6893877B2 (en) * 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
HUP0100777A3 (en) 1998-01-16 2001-12-28 Novo Nordisk As Tripeptides with growth hormone releasing properties, pharmaceutical compositions comprising thereof and their use
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
NZ508057A (en) * 1998-06-03 2003-07-25 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
CA2335112A1 (en) * 1998-06-16 1999-12-23 Hua Zhu Ke Therapeutic combinations for musculoskeletal frailty
PA8471201A1 (en) * 1998-06-16 2000-09-29 Pfizer Prod Inc THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE STROGEN RECEPTOR AND PARATHYROID HORMONE MODULATOR
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CA2341649A1 (en) * 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
PT1112095E (en) 1998-09-11 2003-04-30 Axel Stemberger BIOLOGICALLY ACTIVE IMPLANTS
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
SI1004583T1 (en) * 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
JP2002542151A (en) 1999-02-18 2002-12-10 科研製薬株式会社 Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CA2395996A1 (en) 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
US20020151040A1 (en) 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
WO2001061054A2 (en) * 2000-02-18 2001-08-23 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
ATE310728T1 (en) 2000-05-11 2005-12-15 Bristol Myers Squibb Co TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGEN
DOP2001000154A (en) * 2000-05-25 2002-05-15 Pfizer Prod Inc COMBINATION OF SECRETAGOGOS OF HORMONE OF THE GROWTH AND ANTIDEPRESSANTS
JP2003534377A (en) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド Melanocortin receptor agonist
DE60140285D1 (en) 2000-05-31 2009-12-10 Pfizer Prod Inc Use of growth hormone secretagogues to promote the mobility of the digestive tract
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
BR0113626A (en) 2000-08-30 2003-06-17 Pfizer Prod Inc Sustained-Release Formulations for Growth Hormone Secretors
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) * 2000-09-28 2002-06-30 Pfizer Prod Inc Use of growth hormone secretagogues in conjunction with physical exercise
JP4361271B2 (en) * 2000-10-10 2009-11-11 バイオトローブ・インコーポレイテツド Instruments for assay, synthesis, and storage, and methods of making, using, and operating the same
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003041641A2 (en) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) * 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US8277753B2 (en) 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
KR20050071498A (en) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 Ghrh analogues
AU2003302264A1 (en) 2002-12-20 2004-09-09 Biotrove, Inc. Assay apparatus and method using microfluidic arrays
US20060094108A1 (en) * 2002-12-20 2006-05-04 Karl Yoder Thermal cycler for microfluidic array assays
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) * 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
ATE547404T1 (en) 2003-09-22 2012-03-15 Msd Kk PIPERIDINE DERIVATIVES
US7129561B2 (en) * 2003-11-19 2006-10-31 International Business Machines Corporation Tri-metal and dual-metal stacked inductors
EP1735097B1 (en) 2004-03-12 2016-11-30 Life Technologies Corporation Nanoliter array loading
WO2005097788A2 (en) * 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
PE20060574A1 (en) 2004-07-28 2006-06-24 Glaxo Group Ltd ARILPIPERAZINE SULFONAMIDE DERIVATIVES AS AGONISTS OF GROWTH HORMONE SECRETAGOG RECEPTORS (GHS)
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US12070731B2 (en) 2004-08-04 2024-08-27 Life Technologies Corporation Methods and systems for aligning dispensing arrays with microfluidic sample arrays
ES2388501T3 (en) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Use of growth hormone secretagogues to stimulate the motility of the gastrointestinal system
WO2006023608A2 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
BRPI0610580B8 (en) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd piperidine derivative compound
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (en) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHINE DERIVATIVE
ES2381205T3 (en) 2005-11-10 2012-05-24 Msd K.K. Aza-substituted spiro derivative
WO2007058359A1 (en) * 2005-11-21 2007-05-24 University Of Miyazaki THERAPEUTIC AGENT FOR SKIN OR SKIN REPAIR-PROMOTING AGENT COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
CU23592A1 (en) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech METHOD TO PREVENT AND ELIMINATE FIBROSIS AND OTHER FORMS OF PATHOLOGICAL DEPOSIT IN THE FABRICS APPLYING THE GHRP-6 SECRETAGOGO PEPTIDE
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
WO2007106385A2 (en) 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
MX2009002492A (en) * 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Compounds and methods for 18f labeled agents.
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US20090035215A1 (en) * 2006-10-02 2009-02-05 Ananth Srinivasan Radiofluorination
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
CN101657436A (en) 2007-02-09 2010-02-24 特兰齐姆制药公司 macrocyclic ghrelin receptor modulators and methods of use thereof
JP2010520229A (en) * 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Radiofluorination method
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
JP5319518B2 (en) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
WO2008151512A1 (en) * 2007-06-12 2008-12-18 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Site-specific pegylated linear salmon calcitonin derivatives
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINE DERIVATIVE
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 Spirodiamine-diarylketoxime derivatives
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (en) 2008-10-30 2011-05-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
US10975070B2 (en) * 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20140027284A (en) * 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 Growth hormone releasing factor (grf) analogs and uses thereof
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
KR20150020602A (en) * 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 Ghrelin receptor agonists for the treatment of achlorhydria
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
BR112015006282B1 (en) 2012-09-27 2021-11-23 Aratana Therapeutics, Inc COMPOSITIONS AND USES OF CAPROMORELIN TO CONTROL INAPPETENCE
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
KR20150118158A (en) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 Antidiabetic bicyclic compounds
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP3004100B1 (en) * 2013-05-28 2018-06-27 RaQualia Pharma Inc. Polymorph forms
BR112015030326A2 (en) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
KR102051433B1 (en) * 2013-08-27 2020-01-08 (주)네오팜 A composition and external application for acceleration of muscle differentiation and improving of muscle mass
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2695649C2 (en) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Serine derivatives as ghrelin receptor agonists
KR102431436B1 (en) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP3212648A1 (en) 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
AR117122A1 (en) 2018-11-20 2021-07-14 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC ACID INHIBITORS SEMIALDEHYDE DECARBOXYLASE
CN109320515A (en) * 2018-11-22 2019-02-12 常州大学 A kind of asymmetric synthesis method of Capromorelin chiral intermediate
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
CN120265641A (en) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a agonist, pharmaceutical composition, preparation method and application thereof
CN119285632A (en) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 A method for preparing a caprelin intermediate based on yeast alcohol dehydrogenase-catalyzed oxidation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP0662481A1 (en) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidines and homologs promote release of growth hormone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO136251C (en) * 1971-05-11 1977-08-10 Sandoz Ag ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIDAZINE DERIVATIVES.
DE2221808C2 (en) * 1972-05-04 1985-06-20 Sandoz-Patent-GmbH, 7850 Lörrach Hydrazinopyridazine derivatives, their acid addition salts, processes for their preparation and medicines
JP3670690B2 (en) * 1993-10-04 2005-07-13 トーアエイヨー株式会社 3-pyridazinone derivative, process for producing the same, and cardiovascular agent containing the same
HUT75224A (en) * 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ID18218A (en) * 1995-01-27 1998-03-19 Novo Nordisk As COMPOUND WITH GROWTH HORMONE EXTENSION
AU4534696A (en) * 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1996024580A1 (en) * 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0761219A1 (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamines as growth hormone secretagogues
WO1997006803A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (en) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidines and homologs promote release of growth hormone
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone

Also Published As

Publication number Publication date
HRP960618A2 (en) 1998-04-30
CA2241725A1 (en) 1997-07-10
BR9612465A (en) 1999-07-13
IL138910A0 (en) 2001-11-25
NZ322172A (en) 2000-08-25
WO1997024369A1 (en) 1997-07-10
AU716934B2 (en) 2000-03-09
SK285678B6 (en) 2007-06-07
EG24195A (en) 2008-10-14
SI0869968T1 (en) 2007-08-31
HUP9901246A3 (en) 1999-11-29
CN1113895C (en) 2003-07-09
DE69637063T2 (en) 2008-02-07
JPH11501945A (en) 1999-02-16
ZA9610858B (en) 1998-06-23
AR052506A2 (en) 2007-03-21
HUP9901246A2 (en) 1999-08-30
US6107306A (en) 2000-08-22
TW432073B (en) 2001-05-01
HRP960618B1 (en) 2007-12-31
US20020049196A1 (en) 2002-04-25
NO982991L (en) 1998-08-26
TR199801233T2 (en) 1998-10-21
US6278000B1 (en) 2001-08-21
KR100320167B1 (en) 2003-11-14
US6124264A (en) 2000-09-26
CZ199598A3 (en) 1999-05-12
IL124449A0 (en) 1998-12-06
UA66754C2 (en) 2004-06-15
US6306875B1 (en) 2001-10-23
US6313140B1 (en) 2001-11-06
BR9612465B1 (en) 2010-08-10
ATE361314T1 (en) 2007-05-15
IL138909A0 (en) 2001-11-25
IS4758A (en) 1998-05-26
IL138911A0 (en) 2001-11-25
CN1206422A (en) 1999-01-27
US6482825B2 (en) 2002-11-19
AP9600881A0 (en) 1997-01-31
PL327634A1 (en) 1998-12-21
PE30398A1 (en) 1998-07-21
EP0869968A1 (en) 1998-10-14
PT869968E (en) 2007-07-11
CZ293423B6 (en) 2004-04-14
GT199600100A (en) 1998-06-12
HN1996000085A (en) 1997-06-18
AP9901555A0 (en) 1999-06-30
OA10702A (en) 2001-05-07
AP860A (en) 1999-08-06
TNSN96172A1 (en) 2005-03-15
BG102533A (en) 1999-09-30
IL138911A (en) 2007-07-24
AR004367A1 (en) 1998-11-04
EP0869968B1 (en) 2007-05-02
SK87498A3 (en) 1999-08-06
RS49926B (en) 2008-09-29
KR19990076846A (en) 1999-10-25
DE69637063D1 (en) 2007-06-14
JP3511382B2 (en) 2004-03-29
JP2001213800A (en) 2001-08-07
NO982991D0 (en) 1998-06-26
YU70296A (en) 1999-11-22
MX9805157A (en) 1998-10-31
US6110932A (en) 2000-08-29
NO325135B1 (en) 2008-02-04
SA97170581B1 (en) 2006-03-15
CA2241725C (en) 2002-06-18
IL124449A (en) 2004-06-01
BG64055B1 (en) 2003-11-28
PL186916B1 (en) 2004-03-31
MY135727A (en) 2008-06-30
AU7585096A (en) 1997-07-28
CO4480108A1 (en) 1997-07-09
MA26415A1 (en) 2004-12-20
DK0869968T3 (en) 2007-09-10
ES2285715T3 (en) 2007-11-16

Similar Documents

Publication Publication Date Title
AP756A (en) Dipeptide compounds which are growth hormone secretagoques.
JP5000848B2 (en) Ghrelin-containing pharmaceutical composition
ES2333097T3 (en) USE OF SECRETAGOGS OF GROWTH HORMONE TO STIMULATE GASTROINTESTINAL MOTILITY.
US6313133B1 (en) Sleep quality improvement using a growth hormone secretagogue
US20230120030A1 (en) Long-Acting Adrenomedullin Derivatives
EP3271015B1 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
JPH10509152A (en) Low molecular weight peptide-like growth hormone release promoter
TWI861780B (en) Combination therapy for preventing or treating obesity
AU711884B2 (en) Enhancement of sleep with a growth hormone secretagogue
EP1781311A2 (en) Growth-hormone secretagogues
AU2004281084B2 (en) Use of growth hormone releasing factor analogs in treating patients suffering from wasting
AU2003229724B2 (en) Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
KR101228229B1 (en) Gh secretagogues and uses thereof
AU6133299A (en) Enhancement of return to independent living status with a growth hormone secretagogue
CA2335112A1 (en) Therapeutic combinations for musculoskeletal frailty
US20020160961A1 (en) Compositions for the treatment of the catabolic state of prolonged critical illness
EP1716887B1 (en) Treatment of inclusion body myositis
RU2172742C2 (en) Stimulating agents of growth hormone secretion
RU98112108A (en) STIMULATORS OF THE SECRETION OF GROWTH GROWTH
EA044055B1 (en) USING A NEUROKININ-3 (NK-3) RECEPTOR ANTAGONIST TO INCREASE CIRCULATORY LEPTINA LEVELS IN PATIENTS
HK1036938A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty